Ушбу иш иқтибос қилган ишлар

77 та иш

Иш: Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1)

1. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

   Milton Packer, Stefan D. Anker, Javed Butler +36

   Мақола20204 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.282518

2. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

   John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi +35

   Мақола20193 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.282514

3. Possibilities of dapagliflozin-induced cardioprotection on doxorubicin + cyclophosphamide mode of chemotherapy-induced cardiomyopathy

   Ashot Avagimyan, Mohammad Sheibani, Nana Pogosova +8

   Мақола20233 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.282558

4. TGF-β signaling in health and disease

   Joan Massagué, Dean Sheppard

   Шарҳ мақола20232 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.267622

5. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

   Bernard Zinman, Christoph Wanner, John M. Lachin +9

   Мақола20152 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.282498

6. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

   Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca +17

   Мақола20182 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.282509

7. Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement

   С. Н. Терещенко, М. В. Шестакова, Ф. Т. Агеев +7

   Мақола20202 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.282517

8. Dapagliflozin in Patients with Chronic Kidney Disease

   Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter +11

   Мақола20202 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.282519

9. KEAP1‐NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential

   Enrique Crisman, Pablo Duarte, E. Daudén +4

   Шарҳ мақола20222 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.282546

10. Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis

    Milton Packer

    Шарҳ мақола20222 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.282548

11. A Comprehensive Guide to Sodium Glucose Cotransport Inhibitors

    Christopher Cunningham, Ahmad Jabri, Laith Alhuneafat +1

    Шарҳ мақола20232 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.282552

12. Cardiovascular prevention 2022. Russian national guidelines

    S. А. Boytsov, Nana Pogosova, А. А. Аншелес +34

    Мақола20232 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.282555

13. Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials

    Karan B. Bhanushali, Heena Asnani, Ambica Nair +2

    Шарҳ мақола20242 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.282571

14. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.282499

15. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.282500

16. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.282501

17. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.282502

18. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.282503

19. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.282504

20. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.282505

21. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.282506

22. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.282507

23. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.282508

24. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.282510

25. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.282511